Daldrup-Link and team showed in preclinical models of breast cancer, that treatment with CSF1 (colony stimulating factor 1) monoclonal antibodies significantly reduced ferumoxytol tumor enhancement on delayed T2-weighted MR images and that this effect correlated with a significant decline in TAM quantities in the tumor tissue on histopathology, as determined by CD68 immuno stains and flow cytometry analyses 125. Here, CSF1 is linked to breast carcinoma.